Department of Internal Medicine, Pusan National University School of Medicine, Busan, Korea.
Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.
Respirology. 2016 Feb;21(2):321-8. doi: 10.1111/resp.12677. Epub 2015 Nov 6.
We evaluated the clinical utility of rapid identification of microorganisms in bronchoalveolar lavage (BAL) fluid using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in terms of the clinical outcomes of ventilated patients with pneumonia.
Patients for whom microorganisms were identified via MALDI-TOF MS (from March 2013 to February 2014; post-intervention group) were compared with patients for whom microorganisms were identified using conventional methods (from March 2012 to February 2013; pre-intervention group). All pneumonia types (community-acquired, hospital-acquired, healthcare-associated and ventilator-associated pneumonia) were included in the analysis.
In total, 77 patients (50 men, mean age 67.2 ± 12.5 years) were included (40 patients in the pre-intervention group and 37 in the post-intervention group). The time from BAL fluid collection to microorganism identification and the availability of antimicrobial susceptibility results was shorter in the post- compared with the pre-intervention group (51.9 ± 11.3 vs 67.3 ± 17.4 h, P < 0.001). Also, the time from BAL fluid collection to adjustment of antibiotic therapy was shorter in the post-intervention group (56.5 ± 10.9 vs 73.2 ± 18.5 h, P < 0.001). Microorganism identification via MALDI-TOF MS was independently associated with a shorter intensive care unit (ICU) stay after BAL fluid was drawn (hazard ratio = 2.324, P = 0.007).
Rapid identification of microorganisms in BAL fluid via MALDI-TOF MS was associated with adjustment of antibiotic therapy and a shorter ICU stay after BAL fluid was collected from ventilated patients with pneumonia.
我们评估了使用基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF MS)快速鉴定支气管肺泡灌洗液(BAL)中微生物对肺炎机械通气患者临床结局的临床应用价值。
我们对比了使用 MALDI-TOF MS 鉴定微生物的患者(2013 年 3 月至 2014 年 2 月,干预后组)与使用传统方法鉴定微生物的患者(2012 年 3 月至 2013 年 2 月,干预前组)。所有肺炎类型(社区获得性肺炎、医院获得性肺炎、医源性肺炎和呼吸机相关性肺炎)均纳入本研究。
共纳入 77 例患者(50 例男性,平均年龄 67.2 ± 12.5 岁),其中 40 例为干预前组,37 例为干预后组。与干预前组相比,干预后组从 BAL 液采集到鉴定微生物以及获得抗菌药物药敏结果的时间更短(51.9 ± 11.3 比 67.3 ± 17.4 h,P < 0.001)。此外,干预后组从 BAL 液采集到调整抗生素治疗的时间也更短(56.5 ± 10.9 比 73.2 ± 18.5 h,P < 0.001)。MALDI-TOF MS 鉴定微生物与 BAL 液采集后 ICU 入住时间缩短独立相关(风险比=2.324,P=0.007)。
快速鉴定 BAL 液中的微生物与调整抗生素治疗以及肺炎机械通气患者 BAL 液采集后 ICU 入住时间缩短相关。